Stay updated on NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer
Sign up to get notified when there's something new on the NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer page.

Latest updates to the NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on pembrolizumab for non-small cell lung cancer, while adding new identifiers and collaborators.SummaryDifference37%
- Check30 days agoChange DetectedThe webpage has been updated to include new endpoints for tumor response evaluation and survival statistics, while removing previous data on adverse events and clinical response rates.SummaryDifference29%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer
Enter your email address, and we'll notify you when there's something new on the NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer page.